Clopidogrel has significantly reduced the incidence of recurrent atherothrombotic events in
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …

Background Pivotal clinical trials found that ticagrelor reduced ischaemic complications to a
greater extent than clopidogrel, and also that the benefit gradually increased with the …

Introduction: Clopidogrel is an antiplatelet medication described as a prodrug, which cannot
exert the antiplatelet effect until being biotransformed to the active metabolite. It is commonly …

Purpose A high interindividual variability is observed in the pharmacokinetics of clopidogrel,
a widely used antiplatelet drug. In the present study, a joint parent-metabolite population …

Ticagrelor is a direct-acting P2Y12 receptor antagonist. It is rapidly absorbed and partly
metabolized to the active metabolite AR-C124910XX by CYP3A4 and CYP3A5. Three …

Background After the failure of clarithromycin-and bismuth-based quadruple therapy
(CBQT), levofloxacin-and bismuth-based quadruple therapy (LBQT) is recommended for …

Objective: Osteonecrosis of the femoral head (ONFH) is a severe pathological state with
multiple etiologies. Steroid hormone metabolism-related genes play an important role in …

Introduction We investigated the epidemiology of Cytochrome P450 (CYP) 3A4 genotype
and the relationship between CYP3A4 genotype and alcohol drinking habits. Materials and …

Dual antiplatelet therapy with clopidogrel is a regimen used before and after drug-eluting
stent (DES) implantation. Point-of-care platelet reactivity assays are easy-to-use methods to …

Background: The variability in the clinical response to clopidogrel treatment has been
attributed to genetic factors, but the specific genes and other risk factors remain unclear …